

*Editorial*

# Gamma Delta T Cells ( $\gamma\delta$ T Cells) in Health and Disease: In Memory of Professor Wendy Havran

**Dieter Kabelitz** 

Institute of Immunology, Christian-Albrechts University of Kiel, D-24105 Kiel, Germany;  
dietrich.kabelitz@uksh.de; Tel.: +49-431-50031006

Received: 21 November 2020; Accepted: 25 November 2020; Published: 30 November 2020



Gamma delta ( $\gamma\delta$ ) T cells are a small subset of CD3-positive T cells in the peripheral blood but occur at increased frequency in mucosal tissues. The discovery of a second T-cell receptor 35 years ago was certainly unexpected [1–4]. Looking back, however, it is obvious that the scientific interest in  $\gamma\delta$  T-cell research has been undulating since then. A breakthrough of  $\gamma\delta$  T-cell research was the discovery that the major population of human  $\gamma\delta$  T cells does not recognize peptides presented by Human Leukocyte Antigen (HLA) molecules (like the conventional CD4<sup>+</sup> or CD8<sup>+</sup> T cells carrying the  $\alpha\beta$  T-cell receptor) but rather recognize nonpeptidic phosphorylated molecules secreted by bacteria [5]. Such “phosphoantigens” have been discovered not only in many bacteria and some parasites but also in eukaryotic cells as intermediates of the mevalonate pathway of cholesterol synthesis [6]. Overproduction of phosphoantigens in tumor cells due to a dysregulated mevalonate pathway has been shown to activate tumor-reactive  $\gamma\delta$  T cells [7]. How such phosphoantigens are recognized by  $\gamma\delta$  T cells has been a mystery for many years. A landmark paper by Harly and colleagues identified an indispensable role of the butyrophilin family transmembrane molecules, specifically butyrophilin (BTN) 3A1 [8]. Exciting new studies have recently highlighted a similarly indispensable role of another BTN member, BTN2A1 [9,10]. Other studies have shown that BTN-like molecules are also very important for the regulation of tissue-resident human  $\gamma\delta$  T cells [11]. Taken together, there has been tremendous recent progress in the elucidation of the molecular pathways of how  $\gamma\delta$  T cells (as opposed to conventional  $\alpha\beta$  T cells) are activated and influenced by the local micromilieu. From a translational perspective, the potential advantage of  $\gamma\delta$  T cells for (cancer) immunotherapy has long been recognized. The more detailed knowledge of how  $\gamma\delta$  T cells recognize transformed cells independently of HLA restriction has certainly fueled this interest, as reflected by the increasing number of companies devoted to clinical exploration of  $\gamma\delta$  T-cell immunotherapy [12].

This Special Issue of *Cells* comprises 17 original papers and review articles on various aspects of  $\gamma\delta$  T cells in health and disease. In view of the recent and exciting progress in the field, I thought that this would be a wonderful time to collect contributions from leading experts to share their results and amazing new insights with the scientific community. While preparing this Special Issue, we had to mourn the sudden death of Wendy Havran, a giant in the field of  $\gamma\delta$  T-cell research and an exceptional and close friend to many of us in the  $\gamma\delta$  T-cell world. I appreciate the support of the publishers to devote this Special Issue to the memory of Professor Wendy Havran.

The first paper is an appraisal of Professor Wendy Havran, written by her long-term associate Deborah Witherden. This short editorial illustrates the extraordinary personality of Wendy Havran both as a scientist and as a mentor for a large number of trainees in her lab, many of whom have moved on to take leadership positions at universities or in industry [13].

Four reviews and two original papers in this Special Issue concentrate on characteristics of  $\gamma\delta$  T cells under physiologic conditions, and how  $\gamma\delta$  T cells are activated and interact with other immune cells. Fonseca and colleagues present a thorough phenotypic analysis of  $\gamma\delta$  T cells in a population of 30 Caucasian blood donors with a mean age of 47 years. Even though this is a relatively small cohort,

the results clearly indicate the broad range of variability of  $\gamma\delta$  T-cell subset representation (e.g., V $\delta$ 1 versus V $\delta$ 2) in healthy adult blood donors. This paper also summarizes the available literature about parameters possibly influencing immune cell composition including  $\gamma\delta$  T cells, such as age, gender, and ethnicity [14]. A puzzling issue in  $\gamma\delta$  T-cell research is the analysis of the T-cell receptor (TCR) repertoire under physiological and pathological conditions. As compared to the conventional  $\alpha\beta$  T cells, the number of expressed V $\gamma$  and V $\delta$  genes is very small; there are only six V $\gamma$  genes in humans which can be expressed at the protein level, and monoclonal antibodies have been generated to detect the complete expressed human V $\gamma$  repertoire [15]. This notwithstanding, it is obvious that the recent introduction of high-throughput TCR sequencing methodology has tremendously advanced our knowledge of the clonal composition of the  $\gamma\delta$  TCR repertoire and how it changes during development and aging as well as in pathological situations like infection or tumorigenesis. The current state of the art of this exciting topic is summarized in the expert review by Fichtner et al. [16]. The representation of  $\gamma\delta$  T-cell subsets and utilization of the  $\gamma\delta$  TCR are known to be influenced by age. In humans, there are well-characterized alterations in the relative proportion of major  $\gamma\delta$  T-cell subsets V $\delta$ 1 and V $\delta$ 2 not only at different stages of gestation but also postnatally during the transition from childhood to adulthood and old age. While the underlying mechanisms of age-dependent alterations in the  $\gamma\delta$  T-cell compartment are not precisely known, exposure to chronic infections like cytomegalovirus (CMV) is likely to play a role, as discussed by Xu et al. in this Special Issue [17].

How do  $\gamma\delta$  T cells interact with other immune cells? T cells in general are important for providing helper signals for the activation of antibody-producing B cells. It is well known that  $\gamma\delta$  T cells can interact with B cells through multiple costimulatory pathways including CD40/CD40-ligand, inducible T-cell costimulatory (ICOS/ICOS-ligand), or CD86/CD28. Together with cytokines produced by  $\gamma\delta$  T cells, this may drive the differentiation of B cells into antibody-secreting plasma cells. The interaction is reciprocal, however, and B cells may thus also modulate  $\gamma\delta$  T-cell activation. This as well as interesting additional aspects, namely the possible role of  $\gamma\delta$  T cells in the regulation of autoantibody responses in human autoimmune diseases, are discussed in the paper by Rampoldi et al. [18].

As mentioned above, human V $\gamma$ 9V $\delta$ 2 T cells specifically recognize microbial or tumor-derived phosphoantigens. Members of the butyrophilin transmembrane molecules play an indispensable role in this process. The molecular knowledge of how this is accomplished has tremendously grown in recent years. We now know that it is not only the BTN3A1 molecule that is important but rather that BTN2A1 is equally important. An update of the molecular basis of phosphoantigen recognition by V $\gamma$ 9V $\delta$ 2 T cells is provided by Herrmann et al [19]. These new insights also have practical implications when it comes to the intentional activation (or inhibition) of  $\gamma\delta$  T cells by therapeutic manipulation. TCR-dependent recognition of phosphoantigens is key to the selective activation of V $\gamma$ 9V $\delta$ 2 T cells. However, activation can be modulated by costimulatory signals. In this respect, Serrano and coworkers have investigated the costimulatory effect of ligands for selected Toll-like receptors (TLRs), notably TLR8. They observed that such TLR8 ligands rapidly induced interferon- $\gamma$  production in  $\gamma\delta$  T-cells within the total population of peripheral blood mononuclear cells and also costimulated the phosphoantigen-induced interferon- $\gamma$  production. Quite strikingly, the same TLR8 ligands inhibited the proliferative expansion of  $\gamma\delta$  T cells in vitro. The detailed analysis revealed a critical role of monocytes in both situations, as reported in the paper by Serrano et al. [20].

Although V $\gamma$ 9V $\delta$ 2 T cells recognizing phosphoantigens in the context of butyrophilin molecules are the dominant  $\gamma\delta$  T-cell subset in human peripheral blood, it is well known that major populations of  $\gamma\delta$  T cells are localized in tissues, both in mice and humans. Here,  $\gamma\delta$  T cells seem to exert local immunosurveillance by constantly monitoring tissue integrity. An impressive example is the dendritic epidermal T cells (DETCs) localized in the epidermis of mice, which basically represent a dense network of cells morphologically resembling dendritic cells. In fact, however, DETCs represent a clonal population of  $\gamma\delta$  T cells expressing a monomorphic  $\gamma\delta$  TCR. Professor Wendy Havran has pioneered the discovery and functional analysis of murine DETCs [21], and her group was the first to identify self-ligands that are recognized by the DETCs [22]. Over the years, Wendy has substantially

contributed to the molecular characterization of ligands involved in the activation of DETCs, as well as contributing to the identification of what role these cells play in tissue repair and wound healing [23]. The paper by Wendy Havran's associates Margarete Johnson and Deborah Witherden provides an insightful review on the significance of tissue-resident  $\gamma\delta$  T cells in the epidermis, intestinal epithelium, and adipose tissue [24]. Obviously, however, phosphoantigen-reactive human  $\gamma\delta$  T cells also mediate stress surveillance, since sufficiently high levels of endogenous phosphoantigens (mainly isopentenyl pyrophosphate (IPP)) to activate  $\gamma\delta$  T cells are only produced by stressed and transformed cells, not by healthy cells. Another component of the stress surveillance is the recognition of stress-inducible ligands for the NKG2D receptor expressed on most V $\gamma$ 9V $\delta$ 2 T cells. NKG2D ligands like major histocompatibility complex (MHC) class I-related chain A and B (MICA/B) are expressed upon stress or cellular transformation, thereby enabling NKG2D-positive  $\gamma\delta$  T cells to recognize and respond to stressed/transformed cells. The implications of the various recognition systems for the stress surveillance function of human V $\gamma$ 9V $\delta$ 2  $\gamma\delta$  T cells are discussed by Nussbaumer and Thurnher [25].

The second part of this Special Issue comprises nine review articles and original papers on the role of  $\gamma\delta$  T cells in disease. The majority of these articles address the role of  $\gamma\delta$  T cells in cancer immunity and how these cells can be exploited for immunotherapy. Obviously, however,  $\gamma\delta$  T cells are also involved in other diseases, notably autoimmune diseases and viral infections. It was already mentioned that  $\gamma\delta$  T cells might have a dedicated role in the production of autoantibodies [18]. In continuation, the review by Ilan Bank highlights the multifaceted role of  $\gamma\delta$  T cells in various autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis, and systemic lupus erythematosus. In many instances, it is unclear whether alterations in the  $\gamma\delta$  T-cell compartment are a contributing factor in pathophysiology or are secondary to alterations of other immune cell parameters. This review provides an in-depth overview of what is currently known about  $\gamma\delta$  T cells in autoimmune diseases, both in experimental model systems as well as in patients [26]. Alterations in the  $\gamma\delta$  T-cell compartment are observed during viral infections, notably in HIV-infected people. It has been known for some time that there is a reduction in the proportion of V $\delta$ 2 T cells in HIV-infected donors, frequently associated with a relative and also absolute increase in the proportion of V $\delta$ 1 T cells. Given that V $\delta$ 2 T cells contribute to anti-microbial immunity, it is argued that the depletion of V $\delta$ 2 T cells reflects the exposure to multiple microbes including apathogenic mycobacteria, leading to chronic activation and exhaustion of V $\delta$ 2 T cells. Importantly, the paper by Clohosey *et al.* provides interesting insights how effective anti-retroviral therapy also reconstitutes the functional activity of  $\gamma\delta$  T cells [27].

Given the above-discussed role of  $\gamma\delta$  T cells in immunosurveillance, it comes as no surprise that tremendous efforts have been devoted to delineating the role of  $\gamma\delta$  T cells in tumorigenesis and developing strategies for their potential use in cancer immunotherapy. One of the first studies to clearly show that  $\gamma\delta$  T cells are crucial in local stress surveillance was the demonstration that mice lacking  $\gamma\delta$  T cells (including DETCs) are highly susceptible to multiple regimens of skin carcinogenesis [28]. When addressing the potential role of  $\gamma\delta$  T cells in the immune response to cancer, an important aspect is the analysis of  $\gamma\delta$  T cells within the tumor microenvironment *in situ*. Some years ago, a highly cited paper described the abundance of tumor-associated  $\gamma\delta$  T cells at the transcriptomic level as the single most favorable prognostic marker out of 22 distinct leukocyte subsets in 18,000 tumor samples across 39 different cancer types [29]. Subsequent studies, however, uncovered methodological limitations of this study and—using more detailed and refined computational approaches—described a more selected beneficial role of  $\gamma\delta$  T cells in certain cancer types [30]. While the transcriptome analysis of immune cell abundance is certainly a powerful tool, it seems equally important to detect  $\gamma\delta$  T cells and to analyze their spatial localization within different regions in the tumor by immunohistology and more sophisticated technologies such as high-content imaging and quantitative whole-slide imaging analysis [31]. In this respect, the paper by Chabab *et al.* is a very important contribution to the Special Issue. They have optimized the detection of  $\gamma\delta$  T cells by immunohistochemistry and used this approach to quantify the numbers of  $\gamma\delta$  T cells in healthy tissue and in breast, colorectal, ovarian,

and pancreatic cancer. Their interesting results underscore the role of different tumor environments in the recruitment of  $\gamma\delta$  T cells into the tumor [32].

It is well known that the tumor microenvironment contains multiple elements that are directed towards suppressing efficient antitumor immune responses. These include tumor-associated macrophages (TAM) and myeloid-derived suppressor cells (MDSC) which exert their suppressive effects through multiple pathways, including the production of inhibitory cytokines like transforming growth factor- $\beta$  [33]. Suppressive mechanisms mediated by the tumor cells themselves or tumor-associated stroma can also negatively impact the antitumor activity of  $\gamma\delta$  T cells [34]. Jonescheit and colleagues have investigated the role of indoleamine-2,3-dioxygenase (IDO) and its metabolite kynurenine on the cytotoxic effector activity of human V $\gamma$ 9V $\delta$ 2 T cells against pancreatic adenocarcinoma cells. Their results indicate variable expression of IDO in tumor cells and an inhibitory effect of kynurenine on  $\gamma\delta$  T-cell cytotoxicity, thereby raising the possibility that IDO expression might contribute to tumor escape from  $\gamma\delta$  T-cell attack [35].

While it is important to understand tumor immune escape mechanisms, it seems equally important to increase the activation and effector functions of  $\gamma\delta$  T cells. In this respect, our group has recently reported beneficial effects of vitamin C, which acts as both antioxidant and epigenetic modifier [36]. Ma and colleagues have investigated the effects of mistletoe extracts on the activation of human V $\gamma$ 9V $\delta$ 2 T cells. Mistletoe extracts are popular adjuvants in cancer therapy in certain countries, including Germany. In fact, we reported in 1996 that heat-treated mistletoe extracts contain phosphatase-sensitive and proteinase-resistant substances which activate the same subset of human  $\gamma\delta$  T cells that is known to recognize microbial or tumor-derived phosphoantigens in a BTN3A-dependent manner [37]. In their study, Ma et al. used refined and state-of-the-art approaches to characterize in detail the V $\gamma$ 9V $\delta$ 2 T-cell response to mistletoe extracts, supporting the idea that such herbal drugs might help to boost the antitumor response of  $\gamma\delta$  T cells [38].

Three additional review articles in this Special Issue highlight the current knowledge on the role of  $\gamma\delta$  T-cells in tumor immunity and the current concepts of how to bring  $\gamma\delta$  T cells into clinical application for the treatment of cancer patients [39–41]. Importantly, mice do not have  $\gamma\delta$  T cells which respond to the phosphoantigens known to be the most potent and selective ligands for the human V $\gamma$ 9V $\delta$ 2 T cells. Therefore, conventional mouse models cannot be used to address the role of human V $\gamma$ 9V $\delta$ 2 T cells in antitumor immunity. As an alternative, researchers have used various immunodeficient mouse strains for xenografting human tumor cells and human V $\gamma$ 9V $\delta$ 2 T cells. The review by Künkele et al. also provides a detailed overview of various xenograft models that have been used to study the antitumor reactivity of human  $\gamma\delta$  T cells [39]. These reviews also contain detailed overviews of the current status of clinical trials with in vitro expanded  $\gamma\delta$  T cells (adoptive transfer) or in vivo activation of  $\gamma\delta$  T cells with aminobisphosphonates or phosphoantigens, and they discuss novel approaches to possibly increase the efficacy of  $\gamma\delta$  T-cell-based immunotherapy [39–41]. To date, the clinical benefit of cancer immunotherapy with  $\gamma\delta$  T cells is very limited, and there is certainly room for improvement. However, there are multiple strategies on the horizon which might help to translate  $\gamma\delta$  T-cell immunotherapy into a clinical success, which is also reflected by the increasing number of companies focusing on  $\gamma\delta$  T-cell immunotherapy [12]. The HLA independence is considered a decisive advantage of  $\gamma\delta$  T cells, as adoptive transfer of  $\gamma\delta$  T cells from healthy donors to cancer patients across HLA barriers can be considered and, in fact, has already been performed [42].

The collection of original papers and review articles in this Special Issue provide an up-to-date overview of “hot topics” in current  $\gamma\delta$  T-cell research. Not surprisingly, several contributions focus on the role of  $\gamma\delta$  T cells in immunosurveillance and cancer immunity. The tumor-derived ligands recognized by  $\gamma\delta$  T cells and their HLA independence qualify  $\gamma\delta$  T cells as immune cells important for tumor control and distinct from classical  $\alpha\beta$  T cells and NK cells. We are facing exciting developments in the field of cancer immunotherapy, and the recent foundation of several companies focusing on the antitumor activity of  $\gamma\delta$  T cells firmly supports the notion that  $\gamma\delta$  T cells will play an important role in cell-based immunotherapy.

**Funding:** Research on  $\gamma\delta$  T cells from the author's laboratory has been supported by grants from the Deutsche Forschungsgemeinschaft (DFG Ka 502/19-1) and the Wilhelm-Sander Foundation.

**Acknowledgments:** I am most grateful to all colleagues who contributed a manuscript. Without their support, it would not have been possible to compile this timely Special Issue on the exciting topic of  $\gamma\delta$  T cells!

**Conflicts of Interest:** The author declares no conflict of interest.

## References

1. Saito, H.; Kranz, D.M.; Takagaki, Y.; Hayday, A.C.; Eisen, H.N.; Tonegawa, S. A third rearranged and expressed gene in a clone of cytotoxic T lymphocytes. *Nature* **1984**, *312*, 36–40. [\[CrossRef\]](#)
2. Brenner, M.B.; McLean, J.; Dialynas, D.P.; Strominger, J.L.; Smith, J.A.; Owen, F.L.; Seidman, J.G.; Ip, S.; Rosen, F.; Krangel, M.S. Identification of a putative second T-cell receptor. *Nature* **1986**, *322*, 145–149. [\[CrossRef\]](#) [\[PubMed\]](#)
3. Loh, E.Y.; Lanier, L.L.; Turck, C.W.; Littman, D.R.; Davis, M.M.; Chien, Y.H.; Weiss, A. Identification and sequence of a fourth human T cell antigen receptor chain. *Nature* **1987**, *330*, 569–572. [\[CrossRef\]](#)
4. Jitsukawa, S.; Faure, F.; Lipinski, M.; Triebel, F.; Hercend, T. A novel subset of human lymphocytes with a T cell receptor- $\gamma$  complex. *J. Exp. Med.* **1987**, *166*, 1192–1197. [\[CrossRef\]](#) [\[PubMed\]](#)
5. Constant, P.; Davodeau, F.; Peyrat, M.A.; Poquet, Y.; Puzo, G.; Bonneville, M.; Fournié, J.J. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. *Science* **1994**, *264*, 267–270. [\[CrossRef\]](#) [\[PubMed\]](#)
6. Kabelitz, D. Small molecules for the activation of human gammadelta T cell responses against infection. *Recent Pat. Antiinfect Drug Discov.* **2008**, *3*, 1–9. [\[CrossRef\]](#) [\[PubMed\]](#)
7. Gober, H.J.; Kistowska, M.; Angman, L.; Jenö, P.; Mori, L.; De Libero, G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. *J. Exp. Med.* **2003**, *197*, 163–168. [\[CrossRef\]](#)
8. Harly, C.; Guillaume, Y.; Nedellec, S.; Peigné, C.M.; Mönkkönen, H.; Mönkkönen, J.; Li, J.; Kuball, J.; Adams, E.J.; Netzer, S.; et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human  $\gamma\delta$  T-cell subset. *Blood* **2012**, *120*, 2269–2279. [\[CrossRef\]](#)
9. Rigau, M.; Ostrouska, S.; Fulford, T.S.; Johnson, D.N.; Woods, K.; Ruan, Z.; McWilliam, H.E.G.; Hudson, C.; Tutuka, C.; Wheatley, A.K.; et al. Butyrophilin 2A1 is essential for phosphoantigen reactivity by  $\gamma\delta$  T cells. *Science* **2020**, *367*, 6478. [\[CrossRef\]](#)
10. Karunakaran, M.M.; Willcox, C.R.; Salim, M.; Paletta, D.; Fichtner, A.S.; Noll, A.; Starick, L.; Nöhren, A.; Begley, C.R.; Berwick, K.A.; et al. Butyrophilin-2A1 Directly Binds Germline-Encoded Regions of the V $\gamma$ 9V $\delta$ 2 TCR and Is Essential for Phosphoantigen Sensing. *Immunity* **2020**, *52*, 487–498. [\[CrossRef\]](#)
11. Melandri, D.; Zlatareva, I.; Chaleil, R.A.G.; Dart, R.J.; Chancellor, A.; Nussbaumer, O.; Polyakova, O.; Roberts, N.A.; Wesch, D.; Kabelitz, D.; et al. The  $\gamma\delta$ TCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness. *Nat. Immunol.* **2018**, *19*, 1352–1365. [\[CrossRef\]](#)
12. Kabelitz, D.; Serrano, R.; Kouakanou, L.; Peters, C.; Kalyan, S. Cancer immunotherapy with  $\gamma\delta$  T cells: Many paths ahead of us. *Cell Mol. Immunol.* **2020**, *17*, 925–939. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Witherden, D.A. Wendy L. Havran, PhD: 1955–2020. *Cells* **2020**, *9*, 1039. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Fonseca, S.; Pereira, V.; Lau, C.; Teixeira, M.A.; Bini-Antunes, M.; Lima, M. Human Peripheral Blood Gamma Delta T Cells: Report on a Series of Healthy Caucasian Portuguese Adults and Comprehensive Review of the Literature. *Cells* **2020**, *9*, 729. [\[CrossRef\]](#)
15. Wesch, D.; Hinz, T.; Kabelitz, D. Analysis of the TCR Vgamma repertoire in healthy donors and HIV-1-infected individuals. *Int Immunol.* **1998**, *10*, 1067–1075. [\[CrossRef\]](#) [\[PubMed\]](#)
16. Fichtner, A.S.; Ravens, S.; Prinz, I. Human  $\gamma\delta$  TCR Repertoires in Health and Disease. *Cells* **2020**, *9*, 800. [\[CrossRef\]](#) [\[PubMed\]](#)
17. Xu, W.; Lau, Z.W.X.; Fulop, T.; Larbi, A. The Aging of  $\gamma\delta$  T Cells. *Cells* **2020**, *9*, 1181. [\[CrossRef\]](#) [\[PubMed\]](#)
18. Rampoldi, F.; Ullrich, L.; Prinz, I. Revisiting the Interaction of  $\gamma\delta$  T-Cells and B-Cells. *Cells* **2020**, *9*, 743. [\[CrossRef\]](#) [\[PubMed\]](#)
19. Herrmann, T.; Fichtner, A.S.; Karunakaran, M.M. An Update on the Molecular Basis of Phosphoantigen Recognition by V $\gamma$ 9V $\delta$ 2 T Cells. *Cells* **2020**, *9*, 1433. [\[CrossRef\]](#)



20. Serrano, R.; Wesch, D.; Kabelitz, D. Activation of Human  $\gamma\delta$  T Cells: Modulation by Toll-Like Receptor 8 Ligands and Role of Monocytes. *Cells* **2020**, *9*, 713. [[CrossRef](#)]
21. Havran, W.L.; Poenie, M.; Tigelaar, R.E.; Tsien, R.Y.; Allison, J.P. Phenotypic and functional analysis of gamma delta T cell receptor-positive murine dendritic epidermal clones. *J. Immunol.* **1989**, *142*, 1422–1428. [[PubMed](#)]
22. Havran, W.L.; Chien, Y.H.; Allison, J.P. Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. *Science* **1991**, *252*, 1430–1432. [[CrossRef](#)] [[PubMed](#)]
23. Witherden, D.A.; Watanabe, M.; Garijo, O.; Rieder, S.E.; Sarkisyan, G.; Cronin, S.J.; Verdino, P.; Wilson, I.A.; Kumanogoh, A.; Kikutani, H.; et al. The CD100 receptor interacts with its plexin B2 ligand to regulate epidermal  $\gamma\delta$  T cell function. *Immunity* **2012**, *37*, 314–325. [[CrossRef](#)] [[PubMed](#)]
24. Johnson, M.D.; Witherden, D.A.; Havran, W.L. The Role of Tissue-resident  $\gamma\delta$  T Cells in Stress Surveillance and Tissue Maintenance. *Cells* **2020**, *9*, 686. [[CrossRef](#)] [[PubMed](#)]
25. Nussbaumer, O.; Thurnher, M. Functional Phenotypes of Human V $\gamma$ 9V $\delta$ 2 T Cells in Lymphoid Stress Surveillance. *Cells* **2020**, *9*, 772. [[CrossRef](#)] [[PubMed](#)]
26. Bank, I. The Role of Gamma Delta T Cells in Autoimmune Rheumatic Diseases. *Cells* **2020**, *9*, 462. [[CrossRef](#)]
27. Clohosey, M.L.; Mann, B.T.; Ryan, P.L.; Apanasovich, T.; Maggirwar, S.B.; Pennington, D.J.; Soriano-Sarabia, N. Comparable V $\delta$ 2 Cell Functional Characteristics in Virally Suppressed People Living with HIV and Uninfected Individuals. *Cells* **2020**, *9*, 2568.
28. Girardi, M.; Oppenheim, D.E.; Steele, C.R.; Lewis, J.M.; Glusac, E.; Filler, R.; Hobby, P.; Sutton, B.; Tigelaar, R.E.; Hayday, A.C. Regulation of cutaneous malignancy by gammadelta T cells. *Science* **2001**, *294*, 605–609. [[CrossRef](#)]
29. Gentles, A.J.; Newman, A.M.; Liu, C.L.; Bratman, S.V.; Feng, W.; Kim, D.; Nair, V.S.; Xu, Y.; Khuong, A.; Hoang, C.D.; et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nat. Med.* **2015**, *21*, 938–945. [[CrossRef](#)]
30. Tosolini, M.; Pont, F.; Poupot, M.; Vergez, F.; Nicolau-Travers, M.L.; Vermijlen, D.; Sarry, J.E.; Dieli, F.; Fournié, J.J. Assessment of tumor-infiltrating TCRV  $\gamma$ 9V $\delta$ 2  $\gamma\delta$  lymphocyte abundance by deconvolution of human cancers microarrays. *Oncoimmunology* **2017**, *6*, e1284723. [[CrossRef](#)]
31. Yoo, S.Y.; Park, H.E.; Kim, J.H.; Wen, X.; Jeong, S.; Cho, N.Y.; Gwon, H.G.; Kim, K.; Lee, H.S.; Jeong, S.Y.; et al. Whole-Slide Image Analysis Reveals Quantitative Landscape of Tumor-Immune Microenvironment in Colorectal Cancers. *Clin. Cancer Res.* **2020**, *26*, 870–881. [[CrossRef](#)] [[PubMed](#)]
32. Chabab, G.; Boissière-Michot, F.; Mollevi, C.; Ramos, J.; Lopez-Crapez, E.; Colombo, P.-E.; Jacot, W.; Bonnefoy, N.; Lafont, V. Diversity of Tumor-Infiltrating,  $\gamma\delta$  T-Cell Abundance in Solid Cancers. *Cells* **2020**, *9*, 1537. [[CrossRef](#)] [[PubMed](#)]
33. Wang, Y.; Jia, A.; Bi, Y.; Wang, Y.; Yang, Q.; Cao, Y.; Li, Y.; Liu, G. Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy. *Cancers* **2020**, *12*, 2626. [[CrossRef](#)] [[PubMed](#)]
34. Wesch, D.; Kabelitz, D.; Oberg, H.H. Tumor resistance mechanisms and their consequences on  $\gamma\delta$  T cell activation. *Immunol Rev.* **2020**, *298*, 84–98. [[CrossRef](#)] [[PubMed](#)]
35. Jonescheit, H.; Oberg, H.-H.; Gonnermann, D.; Hermes, M.; Sulaj, V.; Peters, C.; Kabelitz, D.; Wesch, D. Influence of Indoleamine-2,3-Dioxygenase and Its Metabolite Kynurenine on  $\gamma\delta$  T Cell Cytotoxicity against Ductal Pancreatic Adenocarcinoma Cells. *Cells* **2020**, *9*, 1140. [[CrossRef](#)] [[PubMed](#)]
36. Kouakanou, L.; Xu, Y.; Peters, C.; He, J.; Wu, Y.; Yin, Z.; Kabelitz, D. Vitamin C promotes the proliferation and effector functions of human  $\gamma\delta$  T cells. *Cell Mol. Immunol.* **2020**, *17*, 462–473. [[CrossRef](#)]
37. Fischer, S.; Scheffler, A.; Kabelitz, D. Activation of human gamma delta T-cells by heat-treated mistletoe plant extracts. *Immunol Lett.* **1996**, *52*, 69–72. [[CrossRef](#)]
38. Ma, L.; Phalke, S.; Stévigny, C.; Souard, F.; Vermijlen, D. Mistletoe-Extract Drugs Stimulate Anti-Cancer V $\gamma$ 9V $\delta$ 2 T Cells. *Cells* **2020**, *9*, 1560. [[CrossRef](#)]
39. Künkele, K.-P.; Wesch, D.; Oberg, H.-H.; Aichinger, M.; Supper, V.; Baumann, C. V $\gamma$ 9V $\delta$ 2 T Cells: Can We Re-Purpose a Potent Anti-Infection Mechanism for Cancer Therapy? *Cells* **2020**, *9*, 829. [[CrossRef](#)]
40. Liu, Y.; Zhang, C. The Role of Human  $\gamma\delta$  T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy. *Cells* **2020**, *9*, 1206. [[CrossRef](#)]
41. Yazdanifar, M.; Barbarito, G.; Bertaina, A.; Airolidi, I.  $\gamma\delta$  T Cells: The Ideal Tool for Cancer Immunotherapy. *Cells* **2020**, *9*, 1305. [[CrossRef](#)] [[PubMed](#)]

42. Xu, Y.; Xiang, Z.; Alnaggar, M.; Kouakanou, L.; Li, J.; He, J.; Yang, J.; Hu, Y.; Chen, Y.; Lin, L.; et al. Allogeneic V $\gamma$ 9V $\delta$ 2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. *Cell Mol. Immunol.* **2020**. Epub ahead of print. [[CrossRef](#)] [[PubMed](#)]

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).